Vikas Gupta, MD
Internal Medicine · Fredericksburg, VANPI 1710974167
Payments from drug & device makers
Across 186 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$534
- Novo Nordisk$414
- Amgen$323
- Harmony Biosciences LLC$319
- Amarin Pharma, Inc.$203
- AbbVie$191
- plus $1K from 33 others
What the payments were for
- Food & beverage$3,369100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 44 | $534 |
| Novo Nordisk | 22 | $414 |
| Amgen | 19 | $323 |
| Harmony Biosciences LLC | 17 | $319 |
| Amarin Pharma, Inc. | 11 | $203 |
| AbbVie(2 entities) | 11 | $191 |
| Jazz Pharmaceuticals Inc. | 7 | $146 |
| Kowa Pharmaceuticals America, Inc. | 8 | $137 |
| Livanova USA, Inc. | 1 | $102 |
| Eli Lilly | 1 | $101 |
| AstraZeneca | 6 | $101 |
| Neurelis, Inc. | 1 | $96 |
| Bausch Health US, LLC | 3 | $67 |
| Abbott | 3 | $62 |
| Astellas Pharma US Inc | 3 | $57 |
| Amneal Pharmaceuticals LLC | 3 | $57 |
| Esperion Therapeutics, Inc. | 3 | $50 |
| Johnson & Johnson | 2 | $37 |
| Lilly USA, LLC | 1 | $25 |
| Resmed Corp | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Biogen | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Array Biopharma Inc | 1 | $19 |
| Bayer | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Pfizer | 1 | $18 |
| GSK | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Apria Healthcare LLC | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Pernix Therapeutics Holdings, Inc. | 1 | $13 |
| Novartis | 1 | $13 |
| Cook Medical LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,369 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 53 | $112,113 |
| EliquisApixaban | 63 | $86,277 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $47,571 |
| OzempicSemaglutide | 44 | $43,053 |
| JardianceEmpagliflozin | 32 | $41,471 |
| VascepaIcosapent Ethyl | 44 | $39,696 |
| JanuviaSitagliptin Phosphate | 28 | $38,528 |
| SynjardyEmpagliflozin/Metformin Hcl | 21 | $31,345 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $24,628 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $21,249 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $19,597 |
| FarxigaDapagliflozin Propanediol | 19 | $17,675 |
| InvokametCanagliflozin/Metformin Hcl | 12 | $11,527 |
| Doxepin Hcl | 60 | $10,393 |
| SynthroidLevothyroxine Sodium | 70 | $6,939 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $414 | $155,16597 claims |
| PfizerEliquis | $18 | $86,27763 claims |
| AstraZenecaFarxiga, Symbicort | $101 | $22,98034 claims |
| GSKTrelegy Ellipta | $18 | $19,59719 claims |
| Johnson & JohnsonInvokamet | $37 | $11,52712 claims |
| AbbVieSynthroid | $191 | $6,93970 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $57 | $3,037191 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Fredericksburg
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.